Tegaserod-associated ischemic colitis

John K. DiBaise

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Tegaserod, a potent partial agonist of the serotonin 5-HT4 receptor, is used to treat women with constipation-predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.

Original languageEnglish (US)
Pages (from-to)620-625
Number of pages6
JournalPharmacotherapy
Volume25
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Ischemic Colitis
Irritable Bowel Syndrome
Serotonin 5-HT4 Receptor Agonists
Drug Approval
Constipation
Prescriptions
Diarrhea
tegaserod
Physicians
Pharmaceutical Preparations

Keywords

  • IBS
  • Irritable bowel syndrome
  • Ischemic colitis
  • Tegaserod

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Tegaserod-associated ischemic colitis. / DiBaise, John K.

In: Pharmacotherapy, Vol. 25, No. 4, 04.2005, p. 620-625.

Research output: Contribution to journalArticle

DiBaise, John K. / Tegaserod-associated ischemic colitis. In: Pharmacotherapy. 2005 ; Vol. 25, No. 4. pp. 620-625.
@article{e8f94cf9df2a461eb668ffeafd13cccf,
title = "Tegaserod-associated ischemic colitis",
abstract = "Tegaserod, a potent partial agonist of the serotonin 5-HT4 receptor, is used to treat women with constipation-predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.",
keywords = "IBS, Irritable bowel syndrome, Ischemic colitis, Tegaserod",
author = "DiBaise, {John K.}",
year = "2005",
month = "4",
doi = "10.1592/phco.25.4.620.61032",
language = "English (US)",
volume = "25",
pages = "620--625",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Tegaserod-associated ischemic colitis

AU - DiBaise, John K.

PY - 2005/4

Y1 - 2005/4

N2 - Tegaserod, a potent partial agonist of the serotonin 5-HT4 receptor, is used to treat women with constipation-predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.

AB - Tegaserod, a potent partial agonist of the serotonin 5-HT4 receptor, is used to treat women with constipation-predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.

KW - IBS

KW - Irritable bowel syndrome

KW - Ischemic colitis

KW - Tegaserod

UR - http://www.scopus.com/inward/record.url?scp=16344363012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344363012&partnerID=8YFLogxK

U2 - 10.1592/phco.25.4.620.61032

DO - 10.1592/phco.25.4.620.61032

M3 - Article

C2 - 15977922

AN - SCOPUS:16344363012

VL - 25

SP - 620

EP - 625

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -